AU
UK
CA
US
IND
NZ
Company Overview
Picard Medical, Inc. (PMI) serves as a holding company fully owning SynCardia Systems, LLC, a medical technology firm focused on the SynCardia Total Artificial Heart (TAH)—the sole FDA- and Health Canada-approved implantable TAH, with over 2,100 units implanted across 27 countries as a bridge to transplantation for biventricular heart failure patients. The system includes artificial ventricles, external pneumatic drivers for hospital and home use, and drivelines, implanted via standard surgical methods to deliver pulsatile flow. The company's roadmap involves enhancing driver technology, broadening indications to Bridge to Candidacy and long-term use (two years+), expanding globally, and pioneering the fully implantable Emperor TAH as a transplant alternative, with prototypes in testing, animal studies slated for early 2025, and potential FDA approval by 2028. Facing competitors like Carmat's Aeson TAH, BiVACOR's clinical trials, and off-label LVAD combinations, Picard emphasizes its clinical expertise, intellectual property, and advantages in mechanical circulatory support. In 2025, it pursued an NYSE IPO to secure approximately USD 17 million for growth and innovation.
Initial Public Offering
The company launched its IPO on August 29th, 2025, under the ticker PMI and had sold approximately 4,250,000 shares at USD 4.00 share. We had covered this IPO in our ‘Kalkine IPO Report’ on August 18, 2025, and had concluded that this IPO was “Attractive” given it given the financial performance of the company, use of proceeds, and associated risks.
Conclusion
The closing price of $9.60 for Picard Medical, Inc. (NYSE American: PMI) (October 8, 2025) offers IPO investors a 140.00% price surge from the $4.00 IPO price. This realized return is a key factor. However, the company faces deepening financial weaknesses. Despite revenue growth, the net loss increased to $6.72 million, driven by non-cash charges. Crucially, gross profit turned negative, signaling rising costs and financial strain. Given the significant surge from the IPO price and the growing financial risks, investors who participated in the IPO can consider exiting their position at the closing price of $9.60 as on October 08, 2025.
*The reference data in this report has been partly sourced from Refinitiv.
Disclaimer This report has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine). Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website. Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.
Past performance is not a reliable indicator of future performance.
Please wait processing your request...